Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT and 177Lu-PSMA-617 for Hormone Sensitive, Oligometastatic Prostate Cancer
NCT05079698Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2021
- Primary completion
- Oct 2027
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Dose Limiting Toxicity at 1 year. Started Oct 2021; status: active, not recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05079698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05079698.